Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 20 June

Bell Direct
June 20, 2024

Morning Bell 18 June

Bell Direct
June 18, 2024

How to: Directors Interest Tool

Bell Direct
June 17, 2024

How to: Upcoming Dividends tool

Bell Direct
June 17, 2024

How to: Visual Depth Chart

Bell Direct
June 17, 2024

How to: Market to Limit VS Limit

Bell Direct
June 17, 2024

How to: bellinsight

Bell Direct
June 17, 2024